Publications by authors named "M Cotta"
Enterococcus faecalis is responsible for numerous serious infections, and treatment options often include ampicillin combined with an aminoglycoside or dual beta-lactam therapy with ampicillin and a third-generation cephalosporin. The mechanism of dual beta-lactam therapy relies on the saturation of penicillin-binding proteins (PBPs). Ceftobiprole exhibits high affinity binding to nearly all E.
View Article and Find Full Text PDFArticle Synopsis
- Ventriculitis in critically ill neurocritical care patients increases the risk of complications and death, prompting a need for improved antibiotic dosing strategies.
- The study aimed to create a population pharmacokinetic (PK) model for piperacillin-tazobactam (PTZ) by analyzing samples from neurosurgical patients to determine effective dosing for cerebrospinal fluid (CSF) treatment.
- Results showed significant inter-individual variability in drug penetration into CSF, making it difficult to recommend optimal dosing regimens despite some patients achieving high plasma drug levels.
N-acetylcysteine effects on extracellular polymeric substances of Xylella fastidiosa: A spatiotemporal investigation with implications for biofilm disruption.
Int J Antimicrob Agents
November 2024
Article Synopsis
- The study investigates how N-acetylcysteine (NAC) can disrupt extracellular polymeric substances (EPS) in bacterial biofilms, which help protect bacteria from treatments.
- Researchers used microscopy techniques to observe NAC's effects on single cells and early biofilms of the Xylella fastidiosa bacteria.
- The findings suggest that NAC significantly alters both soluble and tightly bound EPS, enhancing bacterial mobility and potentially aiding in the treatment of bacterial infections.
Clinical studies investigating the benefits of beta-lactam therapeutic drug monitoring (TDM) among critically ill patients are hindered by small patient groups, variability between studies, patient heterogeneity, and inadequate use of TDM. Accordingly, definitive conclusions regarding the efficacy of TDM remain elusive. To address these challenges, we propose an innovative approach that leverages data-driven methods to unveil the concealed connections between therapy effectiveness and patient data, collected through a randomized controlled trial (DRKS00011159; 10th October 2016).
View Article and Find Full Text PDFA Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.
Int J Antimicrob Agents
September 2024
Background: Novel beta-lactams show activity against many multidrug-resistant Gram-negative bacteria that cause severe lung infections. Understanding pharmacokinetic/pharmacodynamic characteristics of these agents may help optimise outcomes in the treatment of pneumonia.
Objectives: To describe and appraise studies that report pulmonary pharmacokinetic and pharmacodynamic data of cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/cilastatin/relebactam and meropenem/vaborbactam.